BYSANTI™ (milsaperidone)

About Vanda Pharmaceuticals

Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.

Therapeutic Areas